BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11964308)

  • 1. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells.
    Ogawa R; Streiff MB; Bugayenko A; Kato GJ
    Blood; 2002 May; 99(9):3390-7. PubMed ID: 11964308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
    Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
    Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells.
    Chen TC; Wadsten P; Su S; Rawlinson N; Hofman FM; Hill CK; Schönthal AH
    Cancer Biol Ther; 2002; 1(3):268-76. PubMed ID: 12432276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.
    Moon EY; Lerner A
    Blood; 2003 May; 101(10):4122-30. PubMed ID: 12531792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
    McEwan DG; Brunton VG; Baillie GS; Leslie NR; Houslay MD; Frame MC
    Cancer Res; 2007 Jun; 67(11):5248-57. PubMed ID: 17545604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
    Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
    Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes.
    Ekholm D; Mulloy JC; Gao G; Degerman E; Franchini G; Manganiello VC
    Biochem Pharmacol; 1999 Sep; 58(6):935-50. PubMed ID: 10509746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lixazinone stimulates mitogenesis of Madin-Darby canine kidney cells.
    Cheng J; Thompson MA; Walker HJ; Gray CE; Warner GM; Zhou W; Grande JP
    Exp Biol Med (Maywood); 2006 Mar; 231(3):288-95. PubMed ID: 16514175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.
    Erdogan S; Houslay MD
    Biochem J; 1997 Jan; 321 ( Pt 1)(Pt 1):165-75. PubMed ID: 9003416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle.
    Murthy KS; Zhou H; Makhlouf GM
    Am J Physiol Cell Physiol; 2002 Mar; 282(3):C508-17. PubMed ID: 11832336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.
    Kim DH; Lerner A
    Blood; 1998 Oct; 92(7):2484-94. PubMed ID: 9746789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis.
    Tiwari S; Felekkis K; Moon EY; Flies A; Sherr DH; Lerner A
    Blood; 2004 Apr; 103(7):2661-7. PubMed ID: 14615375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
    Meyers JA; Taverna J; Chaves J; Makkinje A; Lerner A
    Clin Cancer Res; 2007 Aug; 13(16):4920-7. PubMed ID: 17699872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells.
    Kanda N; Watanabe S
    Biochem Pharmacol; 2001 Aug; 62(4):495-507. PubMed ID: 11448460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
    Souness JE; Hassall GA; Parrott DP
    Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
    Michie AM; Lobban M; Müller T; Harnett MM; Houslay MD
    Cell Signal; 1996 Feb; 8(2):97-110. PubMed ID: 8730511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
    Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
    Biochem Pharmacol; 2005 Jan; 69(2):267-75. PubMed ID: 15627479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
    Thompson WJ; Ashikaga T; Kelly JJ; Liu L; Zhu B; Vemavarapu L; Strada SJ
    Biochem Pharmacol; 2002 Feb; 63(4):797-807. PubMed ID: 11992650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.
    Liu S; Veilleux A; Zhang L; Young A; Kwok E; Laliberté F; Chung C; Tota MR; Dubé D; Friesen RW; Huang Z
    J Pharmacol Exp Ther; 2005 Aug; 314(2):846-54. PubMed ID: 15901792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis.
    Osinski MT; Schrör K
    Biochem Pharmacol; 2000 Aug; 60(3):381-7. PubMed ID: 10856433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.